Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant - 25/05/23
Doi : 10.1016/S1473-3099(23)00278-5
Daichi Yamasoba a, e, Keiya Uriu a, d, Arnon Plianchaisuk a, Yusuke Kosugi a, d, Lin Pan a, f, Jiri Zahradnik g, 
The Genotype to Phenotype Japan (G2P-Japan) Consortium
Jumpei Ito a, b, Kei Sato a, b, c, d, f, h, i a Division of Systems Virology, Department of Microbiology and Immunology, The University of Tokyo, Tokyo, Japan
b International Research Center for Infectious Diseases, The University of Tokyo, Tokyo, Japan
c International Vaccine Design Center, The University of Tokyo, Tokyo, Japan
d The Institute of Medical Science, and Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
e Faculty of Medicine, Kobe University, Kobe, Japan
f Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
g First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia
h Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan
i CREST, Japan Science and Technology Agency, Kawaguchi, Japan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
© 2023
Elsevier Ltd. Tous droits réservés.
Vol 23 - N° 6
P. 655-656 - juin 2023 Retour au numéro
Article précédent
- More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants
- Paul A Monach, Westyn Branch-Elliman
- Exploring the value of rapid infection prevention and control assessment for a coordinated multisectoral response
- Vergil de Claro, Ma Rosario Torralba, Laurentiu Stan
Bienvenue sur EM-consulte, la référence des professionnels de santé.